On Sept. 15, 2020, OPKO Health announce it had initiated a Phase 2 trial with RAYALDEEﾮ as a treatment for mild-to-moderate COVID-19. The trial, ﾓA Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of RAYALDEE (calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue),ﾔ was expected to enroll approximately 160 subjects, many with stage 3 or 4 chronic kidney disease who are at higher risk for developing more severe illness.